Efficacy and Safety of Sibutramin-containing Drugs in Patient With Alimentary Obesity

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

240 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-07-03

Study Completion Date

2021-05-21

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is Open multicenter randomized Phase IV study to evaluate the efficacy and safety of the drug Reduxin® Forte, film-coated tablets, in comparison with the drug Reduxin®, capsules, in patients with alimentary obesity was conducted in 5 cities of the Russian Federation (St. Petersburg, Ivanovo, Kirov, Samara, Rostov-on-Don) on the basis of 8 research centers.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Sibutramine-metformin Combination Versus Sibutramine and Metformin Monotherapy in Obese Patients

NCT00941382

Obesity

UNKNOWN PHASE3

The PRIMAVERA Study: Reduxine Safety Monitoring in Patients With Alimentary Obesity

NCT01773733

Alimentary Obesity

COMPLETED

Efficacy and Safety of THR-4109 in Obese Subjects

NCT00485017

Obesity

COMPLETED PHASE2

A Phase 3, Double-blind/Double-dummy, Safety/Efficacy/Superiority of Sibutramine/Topiramate XR in Adults With Overweight

NCT05209984

Overweight Obesity

WITHDRAWN PHASE3

Phase IIb One Year Efficacy and Safety Study of S-2367 in Obese Subjects With Initial 6-Week Low Calorie Diet

NCT00748605

Obesity

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Male and female patients (240 people) inclusive with alimentary obesity, meeting the inclusion criteria and not meeting the non-inclusion criteria, were randomized into 2 groups in a 1:1 ratio. One group (n=120) received sibutramine+ metformin p. o., 1 tablet (850 mg + 10 mg) once per day, the second group (n=120) received sibutramine+ microcrystalline cellulose (MCC) p. o., 1 capsule (10 mg + 158.5 mg) once per day in the morning. On day 30 ± 1, in the absence of a 2 kg weight loss compared to the first visit, the dose was increased in accordance with the medical instruction. The therapy period was 180 days.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Obesity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Reduxin Forte

Arm 1 (n=120) received metformin+sibutramine p. o., 1 tablet (850 mg + 10 mg) once per day. On day 30 ± 1, in the absence of a 2 kg weight loss compared to the first visit, the dose was increased in accordance with the medical instruction. The therapy period was 180 days.

Group Type EXPERIMENTAL

metformin+sibutramine

Intervention Type DRUG

1 tablet (850 mg + 10 mg) once per day in the morning, without chewing and followed with a glass of water, during meals, for 180 days. At Visit 3 (Day 30 ± 1), in the absence of a 2 kg weight loss compared to Visit1 (Day 1), the zero dose was increased to 1 tablet (850 mg + 15 mg)

Reduxin

Arm 2 (n=120) received sibutramine+ microcrystalline cellulose (MCC) p. o., 1 capsule (10 mg + 158.5 mg) once per day in the morning. On day 30 ± 1, in the absence of a 2 kg weight loss compared to the first visit, the dose was increased in accordance with the medical instruction. The therapy period was 180 days.

Group Type ACTIVE_COMPARATOR

sibutramine+ microcrystalline cellulose

Intervention Type DRUG

1 capsule (10 mg + 158.5 mg) once per day in the morning, without chewing and followed with a glass of water, during meals for, 180 days.At Visit 3 (Day 30 ± 1), in the absence of a 2 kg weight loss compared to Visit 1 (Day 1), the zero dose was increased to 1 capsule (15 mg + 153,5 mg)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

metformin+sibutramine

1 tablet (850 mg + 10 mg) once per day in the morning, without chewing and followed with a glass of water, during meals, for 180 days. At Visit 3 (Day 30 ± 1), in the absence of a 2 kg weight loss compared to Visit1 (Day 1), the zero dose was increased to 1 tablet (850 mg + 15 mg)

Intervention Type DRUG

sibutramine+ microcrystalline cellulose

1 capsule (10 mg + 158.5 mg) once per day in the morning, without chewing and followed with a glass of water, during meals for, 180 days.At Visit 3 (Day 30 ± 1), in the absence of a 2 kg weight loss compared to Visit 1 (Day 1), the zero dose was increased to 1 capsule (15 mg + 153,5 mg)

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Reduxin® Forte Reduxin®

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Availability of the Informed Consent Form of the Patient Information Leaflet (PIL) signed and dated by patient.
2. Men and women aged 18 to 65 years inclusive at the time of signing the Informed Consent Form in PIL.
3. The presence of alimentary obesity.
4. BMI \>30 kg/m2.
5. Failure of non-pharmacological treatment at the time of screening (weight loss \<5% within 3 months of treatment).
6. Patient consent to change in diet, eating behavior, and increased physical activity, and adherence to the investigator's recommendations throughout participation in the study
7. Patient's consent to use reliable contraceptive methods through out the study and for 3 weeks after the end of the study. The following people could take part in the study:

* women who have a negative pregnancy test and use the following contraceptive methods: a barrier method (condom or occlusive cap (diaphragm or cervical/vaulted cap)) or a double barrier method of contraception (condom or occlusive cap). The use of estrogen-containing contraceptives was allowed provided that the drug was used in one dosing regimen for at least 3 months prior to study entry and it was planned to use it at the same dosing regimen throughout the study participation. Women incapable of childbearing may also participate in the study (with past history of: hysterectomy, tubal ligation, infertility, menopause for more than 1 year) or
* men with preserved reproductive function using barrier contraceptives, as well as men with infertility or a history of vasectomy

Exclusion Criteria

1. Hypersensitivity to the components of the study drug/comparator drug
2. Secondary (symptomatic) obesity.
3. Diabetes mellitus type I or II in history and/or at the time of screening.
4. Use of a low-calorie (\<1600 kcal/day) diet for 3 months prior to screening.
5. Patients who previously received drugs based on sibutramine.
6. The use of drugs, herbal remedies or dietary supplements for the treatment of obesity less than 3 months prior to screening.
7. Use of systemic glucocorticosteroids for less than 3 months prior to screening.
8. Plan to change current smoking status during the study or quit smoking less than 3 months prior to screening.
9. The need for surgical treatment of obesity during the study or the history of this treatment.
10. Impaired liver function (AST and/or ALT ≥ 2 UNL and/or total bilirubin ≥ 1.5 UNL) at the time of screening.
11. Impaired renal function (creatinine clearance, calculated according to the Cockcroft- Gault formula, less than 45 ml/min) at the time of screening.
12. Acute conditions in which there was a risk of developing impaired renal function:

dehydration (with diarrhea, vomiting), severe infectious diseases, shock (at the time of screening).
13. Cardiovascular diseases (in history and/or at the time of screening): ischemic heart disease (myocardial infarction, angina pectoris), chronic heart failure in the stage of decompensation, occlusive diseases of peripheral arteries, tachycardia (HR\> 90 beats/min (mean for 3 measurements)), arrhythmia, cerebrovascular diseases (stroke, transient disorders of cerebral circulation).
14. Uncontrollable hypertension (blood pressure (BP) \>145/90 mm Hg on screening).
15. History of pulmonary hypertension.
16. Clinically apparent manifestations of acute and chronic diseases that could lead to the development of tissue hypoxia (including respiratory failure, heart failure).
17. Hyperthyroidism.
18. Uncontrolled hypothyroidism at the time of screening (if using thyroid drugs or synthetic thyroid hormones, the drugs must have been used at a stable dose for at least 3 months prior to screening).
19. Subclinical hypothyroidism at the time of screening.
20. Benign prostatic hyperplasia (for men) in history.
21. Pheochromocytoma in history or suspicion of its presence at screening.
22. Angle-closure glaucoma in history.
23. Lactic acidosis (in history and at the time of screening).
24. Chronic alcoholism, acute ethanol poisoning at the time of screening.
25. Pharmacological and drug dependence in history and / or at the time of screening.
26. Serious eating disorders (anorexia nervosa, bulimia nervosa).
27. History of cholelithiasis or presence of symptoms of cholelithiasis within 3 months prior to screening.
28. History of schizophrenia, schizoaffective disorder, bipolar disorder, or other psychiatric disorder or suspected of having them at the time of screening.
29. History of suicide attempt.
30. Syndrome of Gilles de la Tourette (generalized tics) in history.
31. Major surgery or trauma (associated with a risk to the patient's life) in the last 6 months before screening.
32. Planned surgery (elective surgery) at the time of screening
33. Uncontrolled asthma or asthma controlled by steroids.
34. History of seizures (with the exception of febrile seizures in childhood) or an increased risk of developing seizures.
35. HIV, viral hepatitis B and/or C, history of active tuberculosis.
36. The need for the use of drugs from the list of prohibited therapies.
37. Taking other medications that, in the opinion of the investigator, could affect the course and results of the clinical trial.
38. History of malignant neoplasms, except for patients who have not been observed for the disease within the last 5 years, patients with completely healed basal cell skin cancer or completely healed carcinoma in situ.
39. Severe, decompensated or unstable somatic diseases (any disease or condition that threatened the patient's life or worsened the patient's prognosis, and also made it impossible for him to participate in a clinical study).
40. Patient's unwillingness or inability to comply with procedures of the Study Protocol (in the opinion of the investigator).
41. Pregnancy or breastfeeding period (for women).
42. Participation in another clinical trial within 3 months prior to study enrollment.
43. Other conditions that, in the opinion of the investigator, prevented the inclusion of the patient in the study.

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No